Statement on the antigen composition of COVID-19 vaccines

WHO
Apr 29, 2024

Statement on the antigen composition of COVID-19 vaccines


Key points

  • SARS-CoV-2 continues to circulate and evolve with important genetic and antigenic evolution of the spike protein.
  • The objective of an update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants.
  • As the virus is expected to continue to evolve from JN.1, the TAG-CO-VAC advises the use of a monovalent JN.1 lineage as the antigen in future formulations of COVID-19 vaccines.
  • In accordance with WHO SAGE policy, vaccination programmes should continue to use any of the WHO emergency-use listed or prequalified COVID-19 vaccines and vaccination should not be delayed in anticipation of access to vaccines with an updated composition

Share

Copied